The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease.

While survey data is inconclusive at present in terms of the proportion of US payers using the ICER CUA framework [ 63 , 64 ], the emergence of value assessment tools over recent years points to a trend towards a greater interest in assessing value for money, which is supported by an increasing trend in terms of adoption: from 46% intending to use the ICER reports in 2015 to 59% using them in 2016) [ 64 ].

also in 63,971 other papers